Long-term Data Continue to Support Perjeta Regimen for HER2-positive Metastatic Breast Cancer

Long-term Data Continue to Support Perjeta Regimen for HER2-positive Metastatic Breast Cancer
End-of-study data from the CLEOPATRA trial supports the long-term efficacy of Genentech's Perjeta (pertuzumab) plus Herceptin (trastuzumab) and docetaxel chemotherapy for patients with previously untreated HER2-positive metastatic breast cancer. Patients on the Perjeta combination regimen lived a median 16.3 months longer, compared with the control group not receiving Perjeta, an improvement considered "unprecedented" for this type of cancer. The results were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting by Sandra M. Swain, MD, FASCO, a breast cancer specialist and professor at Georgetown University. Trial data were highlighted in the poster, "End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC)." “Our science-driven approach has been transforming standards of care in breast cancer for more than 20 years, and we are excited to present data from a Perjeta study that showed an unprecedented survival benefit for patients living with advanced HER2-positive disease,” Sandra Horning, MD, Roche’s chief medical officer and head of global product development, said in a
Subscribe or to access all post and page content.